PublisherInfo				
PublisherName		BioMed Central		
PublisherLocation		London		
PublisherImprintName		BioMed Central		

DNASE1 mutation in SLE

ArticleInfo			
ArticleID		63	
ArticleDOI		10.1186/ar-2001-70800	
ArticleCitationID		70800	
ArticleSequenceNumber		20	
ArticleCategory	\Box	Paper Report	
ArticleFirstPage		1	
ArticleLastPage	:	3	
ArticleHistory	:	RegistrationDate : 2001–8–14 Received : 2001–8–14 Accepted : 2001–9–7 OnlineDate : 2001–9–10	
ArticleCopyright		Biomed Central Ltd2001	
ArticleGrants	\Box		

ArticleContext	:	130753311
----------------	---	-----------

Ali Hajeer, Affl

Aff1 King Fahad National Guard Hospital, Riyadh, Saudi Arabia

Keywords

Autoantibodies, DNASE1, ds DNA, mutation, nucleosome, SLE

Context

The gene encoding DNASE1 is about 3.2 Kb with nine exons and eight introns. It is localized to chromosome 16p13.3. Systemic lupus erythematosus (SLE) is a multifactorial disease characterized by the presence of antinuclear antibodies (ANAs) directed against naked DNA and entire nucleosomes. Mice deficient in *DNASE1* (knockout) were found to present with SLE-like symptoms, ANA-positive, deposition of immunocomplexes in the glomeruli and glomerulonephritis.

Significant findings

Sequencing *DNASE1* of 20 Japanese SLE patients revealed two with an A? G transversion at position +172 (exon 2), creating a premature stop codon at residue 5. The two patients were female and aged 13 years old and 17 years old with high anti-DNA and Sjorgen syndrome-A (SS-A) antibody titers. Both were heterezygous for the mutation and had substantially lower levels of DNASE1 activity than other SLE patients without the mutation and healthy controls. In addition, SLE patients without the *DNASE1* mutation had lower enzyme activity than the healthy controls. The two patients with the *DNASE1* mutation exhibited levels of nucleosomal antibodies seven to eight times higher than other SLE patients and 70-80 times greater than the healthy controls.

Comments

These results suggest that lower levels of DNASE1 contribute to the SLE pathophysiology. The mutation was uncommon in SLE patients. It was interesting that other family members, who shared the

mutation, did not exhibit symptoms or signs of SLE. Reduced DNASE1 activity affects the rate of removal of chromatin and chromatin-protein complexes, which may influence the expansion of lymphocytes responsive to nuclear antigens. SLE patients who lack the described mutation appear to have lower levels of DNASE1 activity, suggesting that other polymorphisms may exist in the *DNASE1* regulating elements. The gene *DNASE1* does not map to an area known to be in linkage with SLE. This suggests that *DNASE1* is a disease-modifying gene or a severity marker.

Methods

Gene sequencing, PCR-RFLP, DNASE1 activity

Additional information

Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Moroy T: **Features of systemic lupus erythematosus in Dnase1-deficient mice.** *Nat Genet* 2000, **25**:177-181 (PubMed abstract).

References

1. Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, Kuroda Y: Mutation of *DNASE1* in people with systemic lupus erythematosus. Nat Genet. 2001, 28: 313-314.

This PDF file was created after publication.